Stock analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a "sell" rating on the stock.
InspireMD Stock Up 2.0 %
Shares of NYSE:NSPR traded up $0.05 during mid-day trading on Monday, reaching $2.60. 8,307 shares of the stock were exchanged, compared to its average volume of 36,584. The stock's 50 day simple moving average is $2.67 and its 200-day simple moving average is $2.74. InspireMD has a one year low of $2.07 and a one year high of $3.80. The company has a market cap of $79.65 million, a P/E ratio of -3.47 and a beta of 0.62.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Brown Advisory Inc. bought a new stake in InspireMD in the first quarter valued at approximately $27,000. Uniting Wealth Partners LLC bought a new position in InspireMD in the 1st quarter valued at about $27,000. Renaissance Technologies LLC acquired a new stake in InspireMD during the fourth quarter worth approximately $27,000. XTX Topco Ltd bought a new stake in shares of InspireMD during the first quarter worth approximately $38,000. Finally, Legato Capital Management LLC acquired a new stake in InspireMD during the 4th quarter worth approximately $47,000. Institutional investors own 44.78% of the company's stock.
InspireMD Company Profile
(
Get Free Report)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
Featured Stories
Before you consider InspireMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.
While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
